Fluoxetine Impairs Insulin Secretion without Modifying Extracellular Serotonin Levels in MIN6 β-cells

Abstract

Introduction: Pancreatic β-cells synthetize and store Serotonin (5-Hydroxytriptamine, 5HT) which is co-released with insulin. It has been proposed that extracellular 5HT binds to specific cell surface receptors and modulate insulin secretion. On the other hand, Selective Serotonin Reuptake Inhibitor (SSRI) fluoxetine seems to reduce Glucose-Stimulated Insulin Secretion (GSIS). However, it is unknown whether this effect results from changes in extracellular 5HT concentration owed to the blockade of 5HT transporter (SERT) or from non-5HT dependent actions. The aims of this work were: 1) to quantify extracellular 5HT levels and GSIS in β-cell lines, 2) to determine whether extracellular 5HT levels and GSIS are changed by fluoxetine or 5-Hydroxytryptophan (5HTP, the immediate 5HT biosynthetic precursor), and 3) to quantify the expression of Slc6a4 gene (encoding SERT) in β-cell lines in relation to other genes involved in 5HT system.

Material and Methods: β-cell lines MIN6 and RINm5f were subjected to GSIS protocols, after treatment with fluoxetine, 5HTP or 5HT. Insulin and 5HT were quantified by ELISA and HPLC, respectively. Relative mRNA expression was quantified by RT-qPCR.

Results: MIN6 β-cells secretes 5HT in response to glucose, showing a sharp increase in 5HT release when cells were preloaded with 5HTP. Treatment with 5HT or fluoxetine reduces GSIS. Fluoxetine fails to further increases 5HTP-induced elevation of secreted 5HT. MIN6 β-cells express both isoforms of Tryptophan Hydroxylase (Tph1 and Tph2), and have high expression levels of L-Dopa decarboxylase (Ddc), both enzymes involved in 5HT biosynthetic pathway, but do not express the 5HT transporters Slc6a4 or Slc6a3 (the Dopamine-5HT transporter) genes.

Conclusion: The inhibitory effect of fluoxetine on β-cell glucose stimulated insulin secretion is not mediated by blockage of 5HT transporter through SERT.

Key words

β-cell - insulin secretion - serotonin - fluoxetine

• References

• 1 Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009; 60: 355-366
• 2 Nocito A, Dahm F, Jochum W et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 2007; 133: 608-618
• 3 Rosen CJ. Serotonin rising the bone, brain, bowel connection. N Engl J Med 2009; 360: 957-959
• 4 Amireault P, Sibon D, Cote F. Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of paracrine/autocrine serotonergic networks. ACS Chem Neurosci 2013; 4: 64-71
• 5 Paulmann N, Grohmann M, Voigt JP et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol 2009; 7: e1000229
• 6 Walther DJ, Peter JU, Bashammakh S et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2013; 299: 76
• 7 Isaac R, Boura-Halfon S, Gurevitch D et al. Selective Serotonin Reuptake Inhibitors (SSRIs) Inhibit Insulin Secretion and Action in Pancreatic beta Cells. J Biol Chem 2013; 288: 5682-5693
• 8 De Long NE, Hyslop JR, Raha S et al. Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression. J Affect Disord 2014; 166: 6-13
• 9 Ohta Y, Kosaka Y, Kishimoto N et al. Convergence of the insulin and serotonin programs in the pancreatic beta-cell. Diabetes 2011; 60: 3208-3216
• 10 Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med 2007; 9: 1-24
• 11 Di Gialleonardo V, Signore A, Scheerstra EA et al. 11C-hydroxytryptophan uptake and metabolism in endocrine and exocrine pancreas. J Nucl Med 2012; 53: 1755-1763
• 12 Sakano D, Shiraki N, Kikawa K et al. VMAT2 identified as a regulator of late-stage β-cell differentiation. Nat Chem Biol 2014; 10: 141-148
• 13 Kim H, Toyofuku Y, Lynn FC et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010; 16: 804-808
• 14 Ohara-Imaizumi M, Kim H, Yoshida M et al. Serotonin regulates glucose-stimulated insulin secretion from pancreatic β cells during pregnancy. Proc Natl Acad Sci USA 2013; 110: 19420-19425
• 15 Zhang Q, Zhu Y, Zhou W et al. Serotonin Receptor 2C and Insulin Secretion. PLoS One 2013; 8: e54250
• 16 Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385
• 17 Watanabe H, Rose MT, Aso H. Role of peripheral serotonin in glucose and lipid metabolism. Current Opinion in Lipidology 2011; 22: 186-191
• 18 Murphy DL, Lesch KP. Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci 2008; 9: 85-96
• 19 Chen X, Margolis KJ, Gershon MD et al. Reduced serotonin reuptake transporter (SERT) function causes insulin resistance and hepatic steatosis independent of food intake. PLoS One 2012; 7: e32511
• 20 Iordanidou M, Tavridou A, Petridis I et al. The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. Clin Chim Acta 2010; 411: 167-171
• 21 Peralta-Leal V, Leal-Ugarte E, Meza-Espinoza JP et al. Association of a serotonin transporter gene (SLC6A4) 5-HTTLPR polymorphism with body mass index categories but not type 2 diabetes mellitus in Mexicans. Genet Mol Biol 2012; 35: 589-593
• 22 Penckofer S, Doyle T, Byrn M et al. State of the science: depression and type 2 diabetes. West J Nurs Res 2014; 36: 1158-1182
• 23 McIntyre RS, Soczynska JK, Konarski JZ et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5: 157-168
• 24 Biagetti B, Corcoy R. Hypoglycemia associated with fluoxetine treatment in a patient with type 1 diabetes. World J Clin Cases 2013; 1: 169-171
• 25 Ye Z, Chen L, Yang Z et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS One 2011; 6: 21551
• 26 Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports.. Int J Clin Pharm 2011; 33: 484-492
• 27 Potter van Loon BJ, Radder JK, Frolich M et al. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992; 16: S55-S61
• 28 Maheux P, Ducros F, Bourque J et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997; 21: 97-102
• 29 Gelenberg AJ. A review of the current guidelines for depression treatment. J Clin Psychiatry 2010; 71: e15
• 30 Briscoe VJ, Ertl AC, Tate DB et al. Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes 2008; 57: 2453-2460
• 31 Gentili F, Pigini M, Piergentili A et al. Agonists and antagonists targeting the different alpha2-adrenoceptor subtypes. Curr Top Med Chem 2007; 7: 163-186
• 32 Duan H, Wang J. Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther 2010; 335: 743-753